Bayer Schering supports China haemophilia centres
This article was originally published in Scrip
Bayer Scheringhas pledged a total of €1.5 million over the next five years to fund the development of haemophilia treatment centres in China. The firm has linked with the Chinese Society of Hematology to provide equipment, supplies and educational materials to, and support patient and nursing programmes at, the six existing centres in the country, where an estimated 70,000 to 100,000 people suffer from the disorder. The aim is to develop the network to provide a full range of services in support of improved diagnosis and treatment. Bayer Schering markets Kogenate, currently the only recombinant Factor VIII product approved in China.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.